AstraZeneca Earnings Beat, Revenue Narrowly Miss

AstraZeneca earnings topped profit forecasts while revenue was narrowly below expectations in results for the second quarter and six months ended June 30, 2026. Management reaffirmed full-year 2026 guidance and its long-term revenue ambition.

Quarter Results and Guidance

AstraZeneca PLC (NYSE: AZN; LSE: AZN) reported first-half total revenue of $30.7 billion, up 9.0% reported and 6.0% at constant exchange rates (CER). Excluding generic competition impacts on diabetes drug Farxiga and cardiovascular drug Brilinta, revenue rose 11.0% at CER.

For the six months, core earnings per share (EPS) increased 11.0% year-over-year to $5.21, while reported EPS rose 4.0% to $3.60. The board raised the interim dividend by $0.03 to $1.06 per share.

In the second quarter, revenue reached about $15.4 billion, growing roughly 5.0–6.0% year-over-year but narrowly missing consensus estimates. Core EPS rose to $2.63, exceeding the roughly $2.48 forecast. Management reiterated full-year guidance calling for mid- to high-single-digit revenue growth at CER and low-double-digit core EPS growth at CER. The guidance assumes a core tax rate between 18.0% and 22.0% and a low-single-digit positive foreign-exchange impact on revenue.

The combination of a near-term profit beat and a slight revenue shortfall signals stronger underlying earnings momentum amid uneven top-line trends, requiring investors to weigh that momentum against structural pressures elsewhere in the portfolio.

Growth Drivers and Pipeline Challenges

Double-digit growth in oncology and rare-disease medicines drove the group’s first-half expansion, offsetting weaker sales in BioPharmaceuticals. The latter faced pressure from the U.S. loss of exclusivity for Farxiga and China’s volume-based procurement program, which reduces drug prices.

The company disclosed recent late-stage clinical setbacks. The CARDIO-TTRansform trial of Wainua (eplontersen) failed, and a late-stage trial of Ultomiris (ravulizumab) in patients with a vascular complication after stem-cell transplant missed its primary endpoint. These outcomes have intensified scrutiny of the pipeline’s depth even as newer franchises support current growth.

Chief Executive Pascal Soriot reaffirmed the long-term goal of reaching $80.0 billion in total revenue by 2030, a target first outlined at the 2023 investor day. He said management expects more than 20 high-value clinical readouts over the next 18 months, a dense schedule that could influence the medium-term trajectory toward that goal.